Dibenzoazepine CR3 Ligands for Blocking Neisseria and Retrovirus Entry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for infections caused by pathogens that interact with complement receptor 3 (CR3)-expressing cells, such as Neisseria species and retroviruses, are inadequate in effectively inhibiting the binding and entry of these pathogens into host cells.
Innovation Solution
Development of non-carbohydrate, small molecule ligands, particularly dibenzoazepine compounds, that specifically target the alpha subunit I-domain of CR3 to inhibit the interaction of pathogens with CR3-expressing cells, thereby preventing binding and entry.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies (antibiotics, antivirals, antifungals) are used to treat infections, then pathogen activity is inhibited, but pathogen resistance to these therapies develops
Solution Approach 1:
The patent uses complement receptor 3 (CR3) as an intermediary target instead of directly targeting the pathogen. By blocking the interaction between pathogens and host cells through CR3 inhibition, the therapy achieves antimicrobial effects without selecting for pathogen resistance, as the mechanism does not rely on direct pathogen metabolic pathways
Solution Approach 2:
The patent replaces conventional chemical inhibition of pathogen metabolism with a biological mechanism-based approach. Instead of using antibiotics that interfere with bacterial cell wall synthesis or protein production, the invention employs peptides that block host-pathogen interactions at the cellular level, substituting chemical warfare with biological recognition blocking
2Productivity
If host defense mechanisms are enhanced to fight infections, then pathogen clearance is improved, but host tissue damage increases
Solution Approach 1:
Instead of enhancing host defense mechanisms that cause collateral damage, the patent inverts the approach by blocking pathogen adhesion to host cells. This prevents infections before they establish, avoiding the need to activate aggressive host immune responses that damage tissues. The strategy shifts from offensive immune activation to defensive adhesion blocking
Solution Approach 2:
The patent employs preliminary action by blocking pathogen adhesion to host cells before infection can establish. The CR3-inhibiting peptides prevent pathogens from attaching and invading host tissues, stopping the infection process at its earliest stage and preventing subsequent inflammatory damage that would occur with active immune responses
3Reliability
If new antimicrobial mechanisms are developed to overcome resistance, then therapy effectiveness is maintained, but development complexity increases
Solution Approach 1:
The patent employs a universal mechanism by targeting CR3, which is used by multiple different pathogen types including bacteria, viruses, and fungi. A single CR3-inhibiting peptide can potentially protect against diverse pathogens, simplifying development compared to creating separate drugs for each pathogen type while maintaining broad effectiveness
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure relates to a specific dibenzoazepine compound for use in inhibiting or treating an infection of a subject with a pathogen that interacts with a complement receptor 3 (CR3) polypeptide-expressing cell, wherein the pathogen is selected from a Neisseria species and a retrovirus.